These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1268 related articles for article (PubMed ID: 16808798)

  • 1. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma].
    Zhang Y; Ji SR; Feng DX; Ji J; Han TQ
    Ai Zheng; 2003 Mar; 22(3):295-7. PubMed ID: 12654190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer].
    Dai MH; Zhao YP; Cai LX; Zhu Y
    Zhonghua Wai Ke Za Zhi; 2003 May; 41(5):332-5. PubMed ID: 12892584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An application value of detecting K-ras and p53 gene mutation in the stool and pure pancreatic juice for diagnosis of early pancreatic cancer].
    Lu X; Xu T; Qian J
    Zhonghua Yi Xue Za Zhi; 2001 Sep; 81(17):1050-3. PubMed ID: 11758254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Huang C; Bei L; Liu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
    Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer.
    Lu X; Xu T; Qian J; Wen X; Wu D
    Chin Med J (Engl); 2002 Nov; 115(11):1632-6. PubMed ID: 12609076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
    Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
    Zhang S; Ma Y; Yang X
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation.
    Yamaguchi Y; Watanabe H; Yrdiran S; Ohtsubo K; Motoo Y; Okai T; Sawabu N
    Clin Cancer Res; 1999 May; 5(5):1147-53. PubMed ID: 10353750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.
    Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S
    Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detection of mucin producing or malignant cysts.
    Sreenarasimhaiah J; Lara LF; Jazrawi SF; Barnett CC; Tang SJ
    JOP; 2009 Mar; 10(2):163-8. PubMed ID: 19287110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.